Worse treatment response to neoadjuvant chemoradiotherapy in young patients with locally advanced rectal cancer

BMC Cancer

Table 3 Univariate and multivariate analysis of predictive factors for pCR in LARC patients (n = 901)

Variables	Univariate analysis			Multivariate analysis
Variables	HR	95% CI	p value	HR	95% CI	p value
Sex (male vs. female)	1.351	0.973–1.875	0.073
Age (≥40 years vs. < 40 years)	2.087	1.020–4.269	0.044	2.382	1.105–5.137	0.027
ASA	0.964	0.686–1.353	0.831
Distance from the anal verge	0.919	0.856–0.986	0.018	0.949	0.878–1.025	0.181
Tumor size
≤ 1.8 cm	Reference	Reference	< 0.001	Reference	Reference	< 0.001
1.9–3.1 cm	6.764	4.019–11.385	< 0.001	5.806	3.412–9.878	< 0.001
≥ 3.2 cm	2.022	1.212–3.373	0.007	1.853	1.101–3.119	0.020
Time interval between NCRT and surgery	1.041	0.988–1.097	0.131
Pre-NCRT cT stage	0.731	0.553–0.967	0.031	0.816	0.607–1.097	0.177
Pre-NCRT cN stage	0.550	0.338–0.895	0.016	0.560	0.332–0.943	0.029
Post-NCRT CEA level	0.381	0.224–0.647	< 0.001	0.873	0.805–0.946	0.001
Post-NCRT CA19–9 level	0.492	0.219–1.101	0.084
Chemotherapy regimen	1.083	0.783–1.499	0.630
Radication dose reduction	0.978	0.360–2.653	0.965
NCRT complications	0.900	0.641–1.264	0.542

pCR Pathological complete response; NCRT Neoadjuvant chemoradiotherapy; HR Hazard ratio; CI Confidential interval; ASA American Society of Anesthesiologists; CEA Carcinoembryonic Antigen; CA19–9 Carbohydrate Antigen 19–9

ISSN: 1471-2407